← Stock Trading Canary · All insider profiles
INSIDER PROFILE · FR
Nicola Beltraminelli
Chief Development Officer
Profile key: fr|nicola beltraminelli
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 2
- Purchases · 24M
- 2
- Average purchase
- €80,600
- Gross purchase value
- €161,200
- Last purchase
- 2025-12-31
- Completed 20D events
- 2.0
- Outcome status
- INSUFFICIENT_SAMPLE
Latest company: INNATE PHARMA
Companies: INNATE PHARMA
Post-purchase outcomes
Benchmark-relative outcomes are available against CAC 40.
- Excess return = stock return − CAC 40 return over the same period.
- Hit rate = positive excess-return events ÷ completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 2Small sample | 100.0% (2/2) | 0.0% (0/2) | -1.5% | -1.5% | -2.6% |
| 20D | 2Small sample | 100.0% (2/2) | 0.0% (0/2) | -3.3% | -3.3% | -6.1% |
| 60D | 2Small sample | 100.0% (2/2) | 0.0% (0/2) | -16.9% | -16.9% | -25.9% |
| 120D | 2Small sample | 100.0% (2/2) | 50.0% (1/2) | +1.2% | +1.2% | -1.1% |
Research patterns
- First purchase in 12M
- 1/2
- Large purchase ≥ €100k
- 0/2
- Cluster buying · 15D
- 2/2
- Buying the dip · ≥20% below prior 52W high
- 2/2
- Routine / opportunistic
- Not classifiable
Counts are profile-wide, point-in-time research labels. They never affect the insider score or ranking.
Every completed outcome is shown; n<5 is descriptive small-sample evidence and is not scored. Disclosure-level observations published on the same date may share a return path and may not be statistically independent. These results never affect the insider score or ranking.